Gabapentin Should Not Be Used As-Needed (PRN) for Anxiety
Gabapentin is not appropriate for PRN use in anxiety disorders and should only be considered as a scheduled, second- or third-line agent for specific anxiety conditions after first-line therapies have failed. The medication requires regular dosing with gradual titration to achieve therapeutic effect and carries significant risks of dependence, withdrawal, and respiratory depression when combined with other sedatives 1.
Why PRN Dosing Is Not Appropriate
Pharmacological Requirements for Efficacy
Gabapentin requires scheduled dosing with gradual titration to reach therapeutic levels, typically starting at 100-300 mg/day and increasing incrementally over weeks to effective doses of 900-3600 mg/day in divided doses 2, 3.
The FDA-approved dosing regimen specifies three-times-daily administration with maximum intervals of 12 hours between doses, indicating the need for consistent blood levels rather than intermittent use 3.
Clinical trial evidence for anxiety used scheduled daily dosing, not PRN administration—studies demonstrating efficacy in anxiety employed continuous treatment over 4-8 weeks 4, 5.
Guideline-Based Positioning
For generalized anxiety disorder (GAD), first-line treatment consists of SSRIs (escitalopram, sertraline, paroxetine, fluvoxamine) and SNRIs (venlafaxine, duloxetine), not gabapentin 1.
For social anxiety disorder, gabapentin is listed as a second-line option below SSRIs, SNRIs, and pregabalin, and may be used as a third-line agent when first-line therapies fail 1.
For panic disorder, evidence is limited to severely ill patients (Panic and Agoraphobia Scale score ≥20), and even then requires scheduled dosing 4.
Significant Safety Concerns
Dependence and Withdrawal Risks
Gabapentinoids are associated with tolerance, physical dependence, and withdrawal symptoms comparable to benzodiazepines 1.
Approximately 50% of patients receiving gabapentinoids continue therapy for ≥12 months without clear evidence of sustained benefit, highlighting potential for inappropriate long-term use 1.
Gabapentin was classified as a Schedule V controlled substance in the United States due to abuse potential 1.
Respiratory Depression Risk
Concurrent opioid use markedly increases the risk of respiratory depression and fatal overdose; co-prescription should be avoided whenever possible 1.
In 2019, there were 244 deaths due to pregabalin poisoning in England, with rates exceeding those attributed to diazepam, fentanyl, tricyclics, or SSRIs as groups 6.
Among gabapentin visits, 58.4% involved concomitant CNS depressant medications, most frequently antidepressants (24.3%), opioids (22.9%), and benzodiazepines (17.3%) 7.
Common Adverse Effects
Dose-dependent dizziness and sedation are common, which may limit tolerability and impair driving ability 2, 3.
The FDA warns that gabapentin causes significant driving impairment and patients should not operate complex machinery until they assess their response 3.
In controlled trials, somnolence occurred in 19-21% of patients (vs. 5-9% placebo) and dizziness in 17-28% (vs. 7-8% placebo) 3.
Appropriate Alternatives for Acute Anxiety
For Acute Situational Anxiety
Benzodiazepines remain the standard of care for acute anxiety episodes, such as pandemic-related anxiety 1.
Lorazepam 0.5-1 mg PO up to four times daily (maximum 4 mg/24 hours) is appropriate, with dose reduction to 0.25-0.5 mg in older adults 1.
For Chronic Anxiety Management
SSRIs and SNRIs should be first-line pharmacotherapy for generalized anxiety disorder, social anxiety disorder, and panic disorder 1.
Cognitive behavioral therapy (CBT) is strongly recommended for chronic pain management and anxiety (strong recommendation, moderate evidence) 8.
Limited Evidence Base for Psychiatric Use
Less than 1% of outpatient gabapentin use is for FDA-approved indications, with most use being off-label 7.
Among off-label psychiatric uses, only 5.3% of visits listed depressive disorders and 3.5% anxiety disorders 7.
A 2022 systematic review concluded there is minimal evidence for gabapentin in bipolar disorder and insomnia, and it should be used only with strong justification 9.
Evidence does not support gabapentin use for PTSD, OCD, or major depressive disorder 10, 11.
Clinical Bottom Line
If gabapentin is considered for anxiety after first-line therapies fail, it must be prescribed as a scheduled medication with gradual titration starting at 100-300 mg/day, not as PRN therapy 2, 3. The medication requires weeks to reach therapeutic effect, carries significant risks of dependence and respiratory depression (especially with concurrent CNS depressants), and has limited evidence supporting its use in most anxiety disorders 1, 6. For acute anxiety relief, short-acting benzodiazepines remain more appropriate 1.